case_images: PMC8218727_01
case_images: Preoperative MRI (A-C) revealed a 1.94x1.91x2.16-cm well-defined mass located in the sellar and suprasellar regions. It was isointense on T1WI (A) and slightly hyperintense on T2WI (B), and the tumor was strongly and irregularly contrast-enhanced after gadolinium administration (C). Follow-up MRI 3 months (D-F) and 27 months after surgery (G-I) showed complete removal of the lesion, with no sign of recurrence.
case_images: fendo-12-551493-g001.jpg
case_images: PMC8218727_01_fendo-12-551493-g001.jpg
case_images: f1
case_images: Furthermore, the tumor was isointense on the T1-weighted imaging (T1WI; Figure 1A), slightly hyperintense on the T2-weighted imaging (T2WI; Figure 1B), with strong and irregular contrast enhancement after gadolinium administration (Figure 1C). Follow-up MRI analysis demonstrated a total excision of the tumor (Figures 1D-I). Follow-up MRI scans were taken three months postoperatively (Figures 1D-F), demonstrating that the lesion had been completely removed, with no sign of recurrence. During the last follow-up in April 2021 (27 months postoperatively), the patient reported leading a normal daily life without noticeable symptoms, and the follow-up MRI exhibited no recurrence (Figure 1G-I).
case_images: Well-formed perivascular anucleate zones (pseudorosettes) and (true) ependymal rosettes composed of bland cuboidal or columnar tumor cells seen throughout the tumor (A). Immunolabeling was positive for EMA (B) and S-100 (C).
case_images: fendo-12-551493-g002.jpg
case_images: PMC8218727_01_fendo-12-551493-g002.jpg
case_images: f2
case_images: When examining hematoxylin and eosin (H&E)-stained paraffin sections, we observed characteristic and well-formed perivascular anucleate zones (pseudorosettes) and (true) ependymal rosettes composed of bland cuboidal or columnar tumor cells (Figure 2A). Positive staining was found for thyroid transcription factor-1 (TTF-1), neuron-specific enolase, vimentin, and epithelial membrane antigen (EMA; Figure 2B), as well as S-100 (Figure 2C).